title: Adoptive immunotherapy of cancer utilizing genetically engineered lymphocytes.
abstract: It is becoming increasingly clear that adoptive immunotherapy with genetically engineered T cells has the potential to control and even cure cancer in some patients. On the other hand, severe adverse events associated with efficacy have frequently been reported in clinical trials. Current and near-future challenges for the development of adoptive immunotherapy of cancer using genetically engineered T cells include minimization and prediction of adverse events; identification of new and effective targets, including patient-specific mutations; improvement in T cell functionality, persistence, and memory formation capacity; and utilization of allogeneic or cell line-based T cells.
authors.affiliation: Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan, hikeda@clin.medic.mie-u.ac.jp.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ikeda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Shiku
mesh_terms: D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000637:transplantation; D060846:Cell Engineering / Q000379:methods*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000009:adverse effects / Q000379:methods*; D008213:Lymphocyte Activation / Q000276:immunology; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D009363:Neoplasm Proteins / Q000235:genetics / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D011947:Receptors, Antigen, B-Cell / Q000235:genetics* / Q000276:immunology
chemical_list: D000951:Antigens, Neoplasm; C095204:MAGEA4 protein, human; D009363:Neoplasm Proteins; D011947:Receptors, Antigen, B-Cell